MarketBeat
22 Nov 2026, 13:12 UTC · 1h ago
Abeona Therapeutics Sees ZEVASKYN Treatments Picking Up in 2027 as Centers Ramp Up
Impact · against what's priced in
ABEO is positioned for a 2027 ramp-up with significant margin expansion potential and secondary revenue streams, though near-term growth is capped by modest treatment cadences and pending FDA clarity on manufacturing failures. The outlook remains positive but leans on execution of a slow rollout rather than a sudden catalyst.
- ABEO+0.40
No priced-in read yet





